Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece

被引：0
|
作者：
Tzanetakos, C. [1 ]
Kourlaba, G. [2 ]
Hatzikou, M. [3 ]
Antoniou, C. [4 ]
Ioannides, D. [5 ]
Lefaki, I. [6 ]
Petridis, A. [7 ]
Rigopoulos, D. [8 ]
Roussaki-Schulze, V. [9 ]
Sotiriadis, D. [10 ]
Maniadakis, N. [1 ]
机构：
[1] Natl Sch Publ Hlth, Hlth Serv Org & Management, Athens, Greece
[2] Aghia Sophia Childrens Hosp, Collaborat Ctr Clin Epidemiol & Outcomes Res CLEO, Athens, Greece
[3] Novartis Hellas SACI SA, Athens, Greece
[4] Univ Athens, Hosp Venereol Dermatol Dis A Syggros, Athens, Greece
[5] Aristoteleio Univ Thessaloniki, Hosp Skin & Venereal Dis, Thessaloniki, Greece
[6] Hosp Skin & Venereal Dis, Dermatol Clin, Thessaloniki, Greece
[7] Hosp Venereol Dermatol Dis A Syggros, Dermatol Clin, Athens, Greece
[8] Univ Athens, Attikon Univ Hosp Athens, Athens, Greece
[9] Univ Thessaly, Univ Hosp Larissa, Larisa, Greece
[10] Aristoteleio Univ Thessaloniki, Gen Hosp Thessaloniki PAPAGEORGIOU, Thessaloniki, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
cost-effectiveness; plaque psoriasis; secukinumab;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P125
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany
    Augustin, M.
    McBride, D.
    Gilloteau, I.
    O'Neill, C.
    Neidhardt, K.
    Graham, C. N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (12) : 2191 - 2199
  • [32] Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab
    Malakouti, Mona
    Jacob, Sharon E.
    Anderson, Nancy J.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2016, 9 : 347 - 355
  • [33] Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
    Villacorta, Reginald
    Hay, Joel W.
    Messali, Andrew
    PHARMACOECONOMICS, 2013, 31 (09) : 823 - 839
  • [34] Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
    Reginald Villacorta
    Joel W. Hay
    Andrew Messali
    PharmacoEconomics, 2013, 31 : 823 - 839
  • [35] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Krueger, James
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate R.
    Visvanathan, Sudha
    Pamulapati, Chandrasena
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1551 - 1560
  • [36] Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
    Fioranelli, Massimo
    Roccia, Maria Grazia
    Lotti, Torello
    DERMATOLOGIC THERAPY, 2017, 30 (05)
  • [37] Cost-effectiveness of the treatment for moderate to severe psoriasis in Mexico:: Infliximab, etanercept and efalizumab
    Mucino, E.
    Rivas, R.
    Zapata, L.
    VALUE IN HEALTH, 2008, 11 (03) : A288 - A288
  • [38] Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan M.
    Lowry, Simon
    Feldman, Steve
    Wu, Jashin J.
    Armstrong, April W.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 740 - 748
  • [39] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Prieto-Perez, Rocio
    Llamas-Velasco, Mar
    Cabaleiro, Teresa
    Solano-Lopez, Guillermo
    Marquez, Beatriz
    Roman, Manuel
    Ochoa, Dolores
    Talegon, Maria
    Dauden, Esteban
    Abad-Santos, Francisco
    PHARMACOGENOMICS, 2017, 18 (02) : 157 - 164
  • [40] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Dauden, E.
    Prieto-Perez, R.
    Llamas-Velasco, M.
    Cabaleiro, T.
    Abad-Santos, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S188 - S188
12345